Shopping Cart 0
Cart Subtotal
USD 0

Burns-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Burns-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burns-Pipeline Review, H2 2017, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burns-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 4, 1, 14, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).

The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Burns-Overview 6

Burns-Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Burns-Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Burns-Companies Involved in Therapeutics Development 23

AlgiPharma AS 23

Alliance Pharma Plc 23

Amarantus Bioscience Holdings Inc 24

American Gene Technologies International Inc 24

Anterogen Co Ltd 25

CytoTools AG 25

Destiny Pharma Ltd 26

Lakewood-Amedex Inc 26

Madam Therapeutics BV 27

MediWound Ltd 27

Phagelux Inc 28

Phosphagenics Ltd 28

Se-cure Pharmaceuticals Ltd 29

Stratatech Corp 29

USV Pvt Ltd 30

Burns-Drug Profiles 31

(cerium nitrate hexahydrate + silver sulfadiazine)-Drug Profile 31

A-3APO-Drug Profile 32

AG-110-Drug Profile 34

albumin (recombinant)-Drug Profile 35

AyuV-25-Drug Profile 36

Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis-Drug Profile 37

bromelains-Drug Profile 38

Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns-Drug Profile 42

Cell Therapy for Dermatology and Immunology-Drug Profile 44

ENERGIF-711-Drug Profile 46

epidermal growth factor biosimilar-Drug Profile 47

Gene Therapy for Burns-Drug Profile 48

IMSP-001-Drug Profile 49

ISN-001-Drug Profile 50

lidocaine hydrochloride-Drug Profile 52

Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds-Drug Profile 53

Neu-2000-Drug Profile 54

NJ-01SS-Drug Profile 56

Nu-2-Drug Profile 57

Oligomer G for Burn Wounds-Drug Profile 58

P-12-Drug Profile 59

P-148-Drug Profile 60

PEP-04-Drug Profile 61

Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders-Drug Profile 62

Recombinant Protein to Agonize EPCR for Wounds and Burns-Drug Profile 63

SC-106-Drug Profile 64

SFR-9X0125-Drug Profile 65

silver sulfadiazine-Drug Profile 66

Small Molecules for Burns-Drug Profile 67

sodium hypochlorite-Drug Profile 68

SST-024-Drug Profile 69

Vanadis-02-Drug Profile 70

XF-70-Drug Profile 71

Burns-Dormant Projects 72

Burns-Discontinued Products 74

Burns-Product Development Milestones 75

Featured News & Press Releases 75

Appendix 90

Methodology 90

Coverage 90

Secondary Research 90

Primary Research 90

Expert Panel Validation 90

Contact Us 90

Disclaimer 91


List Of Figure

List of Figures

Number of Products under Development for Burns, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Burns, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Burns-Pipeline by AlgiPharma AS, H2 2017

Burns-Pipeline by Alliance Pharma Plc, H2 2017

Burns-Pipeline by Amarantus Bioscience Holdings Inc, H2 2017

Burns-Pipeline by American Gene Technologies International Inc, H2 2017

Burns-Pipeline by Anterogen Co Ltd, H2 2017

Burns-Pipeline by CytoTools AG, H2 2017

Burns-Pipeline by Destiny Pharma Ltd, H2 2017

Burns-Pipeline by Lakewood-Amedex Inc, H2 2017

Burns-Pipeline by Madam Therapeutics BV, H2 2017

Burns-Pipeline by MediWound Ltd, H2 2017

Burns-Pipeline by Phagelux Inc, H2 2017

Burns-Pipeline by Phosphagenics Ltd, H2 2017

Burns-Pipeline by Se-cure Pharmaceuticals Ltd, H2 2017

Burns-Pipeline by Stratatech Corp, H2 2017

Burns-Pipeline by USV Pvt Ltd, H2 2017

Burns-Dormant Projects, H2 2017

Burns-Dormant Projects, H2 2017 (Contd..1), H2 2017

Burns-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Burns Therapeutic Products under Development, Key Players in Burns Therapeutics, Burns Pipeline Overview, Burns Pipeline, Burns Pipeline Assessment


Companies

Burns Therapeutic Products under Development, Key Players in Burns Therapeutics, Burns Pipeline Overview, Burns Pipeline, Burns Pipeline Assessment

Burns-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burns-Pipeline Review, H2 2017, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burns-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 4, 1, 14, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).

The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Burns-Overview 6

Burns-Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Burns-Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Burns-Companies Involved in Therapeutics Development 23

AlgiPharma AS 23

Alliance Pharma Plc 23

Amarantus Bioscience Holdings Inc 24

American Gene Technologies International Inc 24

Anterogen Co Ltd 25

CytoTools AG 25

Destiny Pharma Ltd 26

Lakewood-Amedex Inc 26

Madam Therapeutics BV 27

MediWound Ltd 27

Phagelux Inc 28

Phosphagenics Ltd 28

Se-cure Pharmaceuticals Ltd 29

Stratatech Corp 29

USV Pvt Ltd 30

Burns-Drug Profiles 31

(cerium nitrate hexahydrate + silver sulfadiazine)-Drug Profile 31

A-3APO-Drug Profile 32

AG-110-Drug Profile 34

albumin (recombinant)-Drug Profile 35

AyuV-25-Drug Profile 36

Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis-Drug Profile 37

bromelains-Drug Profile 38

Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns-Drug Profile 42

Cell Therapy for Dermatology and Immunology-Drug Profile 44

ENERGIF-711-Drug Profile 46

epidermal growth factor biosimilar-Drug Profile 47

Gene Therapy for Burns-Drug Profile 48

IMSP-001-Drug Profile 49

ISN-001-Drug Profile 50

lidocaine hydrochloride-Drug Profile 52

Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds-Drug Profile 53

Neu-2000-Drug Profile 54

NJ-01SS-Drug Profile 56

Nu-2-Drug Profile 57

Oligomer G for Burn Wounds-Drug Profile 58

P-12-Drug Profile 59

P-148-Drug Profile 60

PEP-04-Drug Profile 61

Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders-Drug Profile 62

Recombinant Protein to Agonize EPCR for Wounds and Burns-Drug Profile 63

SC-106-Drug Profile 64

SFR-9X0125-Drug Profile 65

silver sulfadiazine-Drug Profile 66

Small Molecules for Burns-Drug Profile 67

sodium hypochlorite-Drug Profile 68

SST-024-Drug Profile 69

Vanadis-02-Drug Profile 70

XF-70-Drug Profile 71

Burns-Dormant Projects 72

Burns-Discontinued Products 74

Burns-Product Development Milestones 75

Featured News & Press Releases 75

Appendix 90

Methodology 90

Coverage 90

Secondary Research 90

Primary Research 90

Expert Panel Validation 90

Contact Us 90

Disclaimer 91


List Of Figure

List of Figures

Number of Products under Development for Burns, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Burns, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Burns-Pipeline by AlgiPharma AS, H2 2017

Burns-Pipeline by Alliance Pharma Plc, H2 2017

Burns-Pipeline by Amarantus Bioscience Holdings Inc, H2 2017

Burns-Pipeline by American Gene Technologies International Inc, H2 2017

Burns-Pipeline by Anterogen Co Ltd, H2 2017

Burns-Pipeline by CytoTools AG, H2 2017

Burns-Pipeline by Destiny Pharma Ltd, H2 2017

Burns-Pipeline by Lakewood-Amedex Inc, H2 2017

Burns-Pipeline by Madam Therapeutics BV, H2 2017

Burns-Pipeline by MediWound Ltd, H2 2017

Burns-Pipeline by Phagelux Inc, H2 2017

Burns-Pipeline by Phosphagenics Ltd, H2 2017

Burns-Pipeline by Se-cure Pharmaceuticals Ltd, H2 2017

Burns-Pipeline by Stratatech Corp, H2 2017

Burns-Pipeline by USV Pvt Ltd, H2 2017

Burns-Dormant Projects, H2 2017

Burns-Dormant Projects, H2 2017 (Contd..1), H2 2017

Burns-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Burns Therapeutic Products under Development, Key Players in Burns Therapeutics, Burns Pipeline Overview, Burns Pipeline, Burns Pipeline Assessment


Companies

Burns Therapeutic Products under Development, Key Players in Burns Therapeutics, Burns Pipeline Overview, Burns Pipeline, Burns Pipeline Assessment

chat_bubbleLet's Chat